CA Patent

CA2799280A1 — Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Assigned to AbbVie Ireland ULC · Expires 2011-12-01 · 14y expired

What this patent protects

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

USPTO Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Drugs covered by this patent

Patent Metadata

Patent number
CA2799280A1
Jurisdiction
CA
Classification
—
Expires
2011-12-01
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.